Overview
Dr. Hearn is an Associate Professor in the Department of Radiation Oncology at the University of Michigan. He completed his medical training at Harvard Medical School and his residency in radiation oncology at Cleveland Clinic. Dr. Hearn investigates mechanisms by which prostate cancer may become resistant to current treatments.Dr. Hearn also treats bladder cancer and has been impressed by the promising responses (sometimes dramatic and long-lasting) that some patients with bladder cancer have when treated with immunotherapy to harness the body’s immune system. He is interested in the intersection of immunotherapy and radiation therapy.Additionally, Dr. Hearn is interested in novel techniques to improve the safety and efficacy of radiation therapy for lung cancer by modulating cytokines relevant to lung injury.
Dr. Hearn is highly rated in 16 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Pleuropulmonary Blastoma, Muscle Invasive Bladder Cancer, and Prostatectomy.
His clinical research consists of co-authoring 20 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Graduate Institution
Residency
Specialties
Board Certifications
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- EPO
- HMO
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- HMO
- INDEMNITY
- POS
- PPO
- OTHER MANAGED MEDICAID
- HMO
- HMO
- POS
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- OTHER COMMERCIAL
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
1500 E Medical Center Dr, Floor B2 C490, Ann Arbor, MI 48109
Ann Arbor, MI 48109
Additional Areas of Focus
Dr. Hearn has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
University Hospital
Dr. Wahl is a physician scientist at the University of Michigan specializing in cancers of the central nervous system. His research focuses on the development of new treatment strategies for brain tumors and his laboratory group is especially interested in interactions between radiation and abnormal metabolism in glioblastoma. In the clinic, he cares for a wide variety of patients with both malignant and benign tumors of the central nervous system. Dr. Wahl is highly rated in 23 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.
University Of Michigan Medical Center
Avraham Eisbruch is a Radiation Oncologist in Ann Arbor, Michigan. Dr. Eisbruch is highly rated in 11 conditions, according to our data. His top areas of expertise are Throat Cancer, Laryngeal Cancer, Dry Mouth, Head and Neck Squamous Cell Carcinoma (HNSCC), and Glossectomy.
University Hospital
Shruti Jolly MD is an Associate Professor and Associate Chair of Community Practices in the Department of Radiation Oncology at the University of Michigan. She received her undergraduate and medical degrees at Wayne State University as a Presidential Scholar. In 2007, she completed her medical training at William Beaumont Hospital in Royal Oak, Michigan where she served as chief resident and received the RSNA Roentgen Resident Research Award. Dr. Jolly then joined the faculty at the University of Michigan Department of Radiation Oncology. Dr. Jolly directs the treatment of thoracic, gynecologic and endocrine malignancies. She also serves as the director of Brachytherapy, specializing in High Dose Rate (HDR) brachytherapy procedures. Additionally, she is the principal investigator of numerous clinical protocols designed to individualize the radiation therapy of lung and gynecologic cancer patients. Dr. Jolly has authored numerous publications in peer-reviewed journals. As Associate chair of Community Practices, she oversees the standardization and quality of care of patients receiving radiation therapy at the numerous UM Radiation Oncology community practices across the state of Michigan. In addition she also serves as a consultant for the Michigan Radiation Oncology Quality Consortium (MROQC) focused on quality improvement in patients undergoing radiation therapy for breast cancer, lung cancer and bone metastases. Dr. Jolly is highly rated in 27 conditions, according to our data. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Adrenal Cancer, and Pleuropulmonary Blastoma.
Frequently Asked Questions about Dr. Jason W. Hearn
How do I make an appointment with Dr. Jason W. Hearn?
You can book an appointment with Dr. Jason W. Hearn by calling their office at 734-936-4300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Jason W. Hearn a top-rated expert for Prostate Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jason W. Hearn is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Jason W. Hearn specialize in?
While Dr. Jason W. Hearn is a Radiation Oncology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.
Does Dr. Jason W. Hearn participate in research or clinical trials?
Yes. Dr. Jason W. Hearn has published 20 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Jason W. Hearn's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. Jason W. Hearn accept my insurance?
Dr. Jason W. Hearn accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 734-936-4300 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Familial Prostate CancerDr. Hearn isDistinguished. Learn about Familial Prostate Cancer.
- Prostate CancerDr. Hearn isDistinguished. Learn about Prostate Cancer.
- Advanced
- Adult Soft Tissue SarcomaDr. Hearn isAdvanced. Learn about Adult Soft Tissue Sarcoma.
- Bone TumorDr. Hearn isAdvanced. Learn about Bone Tumor.
- Epithelioid SarcomaDr. Hearn isAdvanced. Learn about Epithelioid Sarcoma.
- Ewing SarcomaDr. Hearn isAdvanced. Learn about Ewing Sarcoma.
- FibrosarcomaDr. Hearn isAdvanced. Learn about Fibrosarcoma.
- LiposarcomaDr. Hearn isAdvanced. Learn about Liposarcoma.
- Experienced
- Acinic Cell Carcinoma of Salivary Glands
- Adenoid Cystic CarcinomaDr. Hearn isExperienced. Learn about Adenoid Cystic Carcinoma.
- Adrenal CancerDr. Hearn isExperienced. Learn about Adrenal Cancer.
- Adrenocortical CarcinomaDr. Hearn isExperienced. Learn about Adrenocortical Carcinoma.
- ALK-Positive Non-Small Cell Lung Cancer
- Alveolar Soft Part SarcomaDr. Hearn isExperienced. Learn about Alveolar Soft Part Sarcoma.